Solid Biosciences Inc. SLDB
6.22 USD +0.21 (+3.58%)
Nov 3, 2026, 3:25 PM EST
6.09 Day range 6.32
3.79 52-week range 11.45
- YTD
- +10.20%
- 1 year
- +19.52%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 18.67 +200.3% upside
Now 6.22
- Target (low)
- 11.00
- Target (mean)
- 18.67
- Target (high)
- 26.00
Ratings (0m) 13 13 buy · 0 hold · 0 sell
- Strong buy4
- Buy9
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 13
- 1 month ago 12
- 2 months ago 14
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.41286 | -0.53 – -0.34 | -0.48 | +14.0% | 0 | 0.0% | 13 |
| Next quarter | -0.42488 | -0.54 – -0.34 | -0.53 | +19.8% | 0 | 0.0% | 13 |
| Current year | -1.76 | -2.39 – -1.55 | -1.99 | +11.6% | 0 | 0.0% | 13 |
| Next year | -1.75 | -2.40 – -1.21 | -1.76 | +0.8% | 9.96M | 0.0% | 13 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 27, 2026 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Aug 21, 2026 | Truist Securities | Maintained | Buy | Buy |
| Jun 3, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| May 18, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| May 13, 2026 | Wedbush | Maintained | Outperform | Outperform |
| May 13, 2026 | Piper Sandler | Maintained | Overweight | Overweight |
| Mar 25, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Mar 23, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 20, 2026 | Guggenheim | Initiated | — | Buy |
| Mar 20, 2026 | Chardan Capital | Maintained | Buy | Buy |
| Mar 20, 2026 | Needham | Reiterated | Buy | Buy |
| Mar 12, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Mar 12, 2026 | Chardan Capital | Maintained | Buy | Buy |
| Mar 11, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Feb 9, 2026 | Needham | Reiterated | Buy | Buy |
| Jan 14, 2026 | Needham | Reiterated | Buy | Buy |
| Dec 4, 2025 | Needham | Initiated | — | Buy |
| Nov 5, 2025 | Citigroup | Maintained | Buy | Buy |
| Nov 5, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Nov 4, 2025 | Barclays | Maintained | Overweight | Overweight |
| Nov 4, 2025 | Chardan Capital | Maintained | Buy | Buy |
| Aug 14, 2025 | Chardan Capital | Maintained | Buy | Buy |
| Aug 14, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Aug 13, 2025 | Wedbush | Maintained | Outperform | Outperform |
| Jun 26, 2025 | Citigroup | Initiated | — | Buy |
| Jun 17, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jun 6, 2025 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| May 19, 2025 | Chardan Capital | Maintained | Buy | Buy |
| May 16, 2025 | Piper Sandler | Maintained | Overweight | Overweight |
| May 16, 2025 | Wedbush | Maintained | Outperform | Outperform |